Nanobiotix completes €25.1M private placement
Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A
Commercial Banking: June 22nd Edition
Understanding Loss Given Default A Review of Three Approaches
Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy
Nanobiotix SA closed a private placement of 1,596,527 new shares priced at €15.75 apiece to raise €25.1 million for the development of its cancer treatment NBTXR3.
The shares issued represent 9.99% of the French company.